Evidence map›Paper›PMID 30128811›Full record

ReviewMedical oncology (Northwood, London, England)2018

Management of locally advanced anal canal carcinoma with intensity-modulated radiotherapy and concurrent chemotherapy.

Guillaume Klausner, Eivind Blais, Raphaël Jumeau, Julian Biau, Mailys de Meric de Bellefon, Mahmut Ozsahin, Thomas Zilli, Raymond Miralbell, Juliette Thariat, Idriss Troussier

Abstract readReview
PubMed Publisher
In one paragraph

Review in Medical oncology (Northwood, London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Additional Value of 2-[Journal of clinical medicine · 2020
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guillaume KlausnerRadiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Eivind BlaisRadiation Oncology Department, Centre Hospitalier Universitaire (CHU) La Pitié-Salpêtrière Charles-Foix, Sorbonne University, 47-83 Boulevard de l'Hôpital, 75013, Paris, France.
Raphaël JumeauRadiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Julian BiauRadiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Mailys de Meric de BellefonRadiation Oncology Department, Institut du Cancer de Montpellier Val d'Aurelle, Montpellier University, 208 Avenue des Apothicaires, 34298, Montpellier, France.
Mahmut OzsahinRadiation Oncology Department, Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011, Lausanne, Switzerland.
Thomas ZilliRadiation Oncology Department, Hôpitaux Universitaires de Genève (HUG), Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.
Raymond MiralbellRadiation Oncology Department, Hôpitaux Universitaires de Genève (HUG), Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland.
Juliette ThariatRadiation Oncology Department, François Baclesse Center/ARCHADE, Normandy University, 3 Avenue du Général Harris, 14000, Caen, France.
Idriss TroussierRadiation Oncology Department, Hôpitaux Universitaires de Genève (HUG), Rue Gabrielle-Perret-Gentil 4, 1211, Geneva 14, Switzerland. idrisstroussier@hotmail.com.ORCID http://orcid.org/0000-0001-9355-0471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The best curative option for locally advanced (stages II-III) squamous-cell carcinomas of the anal canal (SCCAC) is concurrent chemo-radiotherapy delivering 36-45 Gy to the prophylactic planning target volume with an additional boost of 14-20 Gy to the gross tumor volume with or without a gap-period between these two sequences. Although 3-dimensional conformal radiotherapy led to suboptimal tumor coverage because of field junctions, this modality remains a standard of care. Recently, intensity-modulated radiotherapy (IMRT) techniques improved tumor coverage while decreasing doses delivered to organs at risk. Sparing healthy tissues results in fewer severe acute toxicities. Consequently, IMRT could potentially avoid a gap-period that may increase the risk of local failure. Furthermore, these modalities reduce severe late toxicities of the gastrointestinal tract as well as better functional conservation of anorectal sphincter. This report aims to critically review contemporary trends in the management of locally advanced SCCAC using IMRT and concurrent chemotherapy.

Indexed as

Disease ManagementAntineoplastic AgentsAnus NeoplasmsCarcinoma, Squamous CellCombined Modality TherapyHumansNeoplasm StagingRadiotherapy, Intensity-ModulatedAntineoplastic AgentsAnal canal, CancerChemo-radiotherapyHelical tomotherapyIntensity-modulated radiation therapySquamous-cell carcinomaVolumetric modulated arc therapy

Identifiers

PMID30128811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.